PROSPECTIVE STUDY OF A MIXED COXSACKIE VIRUS B3 AND B4 OUTBREAK OF UPPER RESPIRATORY ILLNESS IN A CHILDREN'S HOME

PEDIATRICS ◽  
1972 ◽  
Vol 49 (5) ◽  
pp. 744-752
Author(s):  
John C. Hierholzer ◽  
Steven R. Mostow ◽  
Walter R. Dowdle

In the late summer of 1968 an outbreak of moderately severe upper respiratory illness occurred among the 120 children living in a children's home. Coxsackie viruses B3 and B4 were isolated from throat swabs and eye swabs of 21 children who were clinically ill. Neutralization tests were performed on serum specimens collected from each child before, during, and after the outbreak. Fifty-two percent of the children in the home experienced an infection with B3 or B4, 10% were sequentially infected with both types, and 38% remained uninfected. Coxsackie B3 accounted for 57% of all infections, and B4, for 43%. Infection was clearly related to age, and to preexisting antibody. Preexisting B3 and B4 serum neutralizing antibody levels of 1:20 and greater were fully protective against reinfection by the respective virus type. These viruses caused a wide spectrum of symptoms and physical findings which ranged from inapparent infections to aseptic meningitis. Conjunctivitis, exudative tonsillopharyngitis, otitis, and enanthem, were more frequently associated with B3 than B4, and aseptic meningitis was more frequently associated with B4 than B3. One child, experiencing a distinctly biphasic pattern of illness, exhibited a delayed antibody response concomitant with persistent virus shedding from the throat for a duration of 57 days. Using figures corrected for the effect of protective preexisting antibody, the reported illness rate for Coxsackie B3 in the total population was 24%, and the unreported illness rate was 21%; the ratio was 1:1. For type B4, the reported rate was 18% and the unreported rate 38%, for a 1:2 reported: unreported ratio.

PEDIATRICS ◽  
1964 ◽  
Vol 33 (4) ◽  
pp. 534-540
Author(s):  
Sumner Berkovich ◽  
Sidney Kibrick

A late summer outbreak of illness involving newborn infants and mothers is described. Seven infants and five mothers were studied. Although three enterovirus types were recovered from the infants, the outbreak was associated with infection by a variant of ECHO 11. Clinical signs included fever, diarrhea, upper respiratory disease, and aseptic meningitis. In three infants the antibody response significantly exceeded that of the mother. The evidence for an etiologic association of ECHO 11 infection with disease is reviewed.


PEDIATRICS ◽  
1967 ◽  
Vol 39 (2) ◽  
pp. 220-226
Author(s):  
C. George Ray ◽  
Kathryn L. Plexico ◽  
Herbert A. Wenner ◽  
Tom D. Y. Chin

An outbreak of respiratory illness in a children's home, associated with Coxsackie B4 infection, occurred in the summer of 1964. The illness was mild, characterized primarily by mild to moderate pharyngitis, fever, and rhinorrhea. The duration of symptoms was 3 to 7 days. No pleurodynia, aseptic meningitis, or other syndromes frequently associated with Coxsackie B4 were noted. An analysis of sera available from both before and after the outbreak showed that all children without preexisting antibody titers (<1:8) had serological evidence of infection following the outbreak; one-third of the children with preexisting antibody titer (≥1:8) also showed evidence of reinfection. The ratio of subclinical to clinical infections was 3.4 to 1. The data also suggest that the presence of preexisting antibodies did not prevent the development of respiratory illness. The high prevalence of Coxsackie B4 antibodies in this group and in other studies is noted and may be related to a broad clinical spectrum with a probable preponderance of minor illnesses and frequent inapparent infections.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kathryn A. Ryan ◽  
Kevin R. Bewley ◽  
Susan A. Fotheringham ◽  
Gillian S. Slack ◽  
Phillip Brown ◽  
...  

AbstractThere is a vital need for authentic COVID-19 animal models to enable the pre-clinical evaluation of candidate vaccines and therapeutics. Here we report a dose titration study of SARS-CoV-2 in the ferret model. After a high (5 × 106 pfu) and medium (5 × 104 pfu) dose of virus is delivered, intranasally, viral RNA shedding in the upper respiratory tract (URT) is observed in 6/6 animals, however, only 1/6 ferrets show similar signs after low dose (5 × 102 pfu) challenge. Following sequential culls pathological signs of mild multifocal bronchopneumonia in approximately 5–15% of the lung is seen on day 3, in high and medium dosed groups. Ferrets re-challenged, after virus shedding ceased, are fully protected from acute lung pathology. The endpoints of URT viral RNA replication & distinct lung pathology are observed most consistently in the high dose group. This ferret model of SARS-CoV-2 infection presents a mild clinical disease.


Vaccines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 50
Author(s):  
Lei Zuo ◽  
Wenjun Yan ◽  
Zhou Song ◽  
Hao Li ◽  
Xin Xie ◽  
...  

Avian coronavirus infectious bronchitis virus (IBV) causes severe economic losses in the poultry industry, but its control is hampered by the continuous emergence of new genotypes and the lack of cross-protection among different IBV genotypes. We designed a new immunogen based on a spike with the consensus nucleotide sequence (S_con) that may overcome the extraordinary genetic diversity of IBV. S_con was cloned into a pVAX1 vector to form a new IBV DNA vaccine, pV-S_con. pV-S_con could be correctly expressed in HD11 cells with corresponding post-translational modification, and induced a neutralizing antibody response to the Vero-cell-adapted IBV strain Beaudette (p65) in mice. To further evaluate its immunogenicity, specific-pathogen-free (SPF) chickens were immunized with the pV-S_con plasmid and compared with the control pVAX1 vector and the H120 vaccine. Detection of IBV-specific antibodies and cell cytokines (IL-4 and IFN-γ) indicated that vaccination with pV-S_con efficiently induced both humoral and cellular immune responses. After challenge with the heterologous strain M41, virus shedding and virus loading in tissues was significantly reduced both by pV-S_con and its homologous vaccine H120. Thus, pV-S_con is a promising vaccine candidate for IBV, and the consensus approach is an appealing method for vaccine design in viruses with high variability.


1975 ◽  
Vol 258 (1 Second Confer) ◽  
pp. 513-522 ◽  
Author(s):  
John L. Coulehan ◽  
Louis Kapner ◽  
Susan Eberhard ◽  
Floyd H. Taylor ◽  
Kenneth D. Rogers

2014 ◽  
Vol 39 ◽  
pp. 194-203 ◽  
Author(s):  
Arwel W. Jones ◽  
Simon J.S. Cameron ◽  
Rhys Thatcher ◽  
Marikka S. Beecroft ◽  
Luis A.J. Mur ◽  
...  

2010 ◽  
Vol 27 (3) ◽  
pp. e166-e172 ◽  
Author(s):  
Alexandre Moreira ◽  
Franco Arsati ◽  
Ynara Bosco de Oliveira Lima-Arsati ◽  
Antonio Carlos Simões ◽  
Vera Cavalcanti de Araújo

1985 ◽  
Vol 15 (3) ◽  
pp. 231-237 ◽  
Author(s):  
Hiroshi Ichimura ◽  
Kohichi Shimase ◽  
Ikuo Tamura ◽  
Eiji Kaneto ◽  
Osamu Kurimura ◽  
...  

2021 ◽  
Vol 27 (2) ◽  
pp. 1-6
Author(s):  
Ashikin Mohd Nordin ◽  
Jean Jun Ong ◽  
Juriza Ismail ◽  
Norazlin Kamal Nor ◽  
Sau Wei Wong ◽  
...  

Streptococcus pneumoniae (S pneumoniae) can cause a wide spectrum of diseases which includes upper respiratory tract infection as well as more severe invasive disease such as meningitis. Meningitis may be caused by invasion of the organism through the blood brain barrier, either via haematological spread or from an adjacent focus of infection such as the ears. We describe two infants with pneumococcal meningitis and silent mastoiditis. They both presented with a classical history to suggest meningitis with no apparent focus of infection. A brain imaging was done in the first infant to look for the underlying cause of his focal seizure and in the second infant, to assess for complications of meningitis, as he had a slow recovery. While they did not have any clinical signs to point towards the diagnosis, they were both diagnosed to have acute mastoiditis from brain imaging. We would like to highlight the importance of brain imaging in excluding silent mastoiditis in infants with meningitis, particularly in those whose clinical course appears atypical.


2021 ◽  
Vol 218 (7) ◽  
Author(s):  
Laura Solforosi ◽  
Harmjan Kuipers ◽  
Mandy Jongeneelen ◽  
Sietske K. Rosendahl Huber ◽  
Joan E.M. van der Lubbe ◽  
...  

Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.


Sign in / Sign up

Export Citation Format

Share Document